SOURCE: Sunwin International Neutraceuticals, Inc.

November 29, 2005 08:00 ET

Shandong Province Government Submits Fast Track Application for New Treatment for Avian Flu Virus

FORT LAUDERDALE, FL and QUFU, CHINA -- (MARKET WIRE) -- November 29, 2005 -- Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production and distribution of Chinese herbs, veterinary medicines and low calorie natural sweetener (Stevia) in China, will seek approval for "Hypericin" as a new veterinary medical application to treat avian flu. The Department of Livestock Farming for Shandong Province Government has recently submitted a fast-track application to the Livestock Farming Bureau of China Ministry of Agriculture for approval of Hypericin on behalf of Sunwin International Neutraceuticals, Inc. as a new veterinary medicine to treat avian flu virus. Hypericin is a derivative of St. Johns Wort, which is an English word for a Chinese herb manufactured by Sunwin. Sunwin has manufactured Hypericin since 1997.

In recent laboratory tests, Hypericin has proven effective as a treatment for poultry infected with strands of the avian flu. The South China Agricultural University has recently finished a clinic test of a medicine developed by the Chinese Academy of Agricultural Sciences. The result showed hypericin, which is isolated from hypericum perforatum, had cured all poultry infected by the deadly H5N1 avian flu for the experiment. The in vitro experiments indicated that when H5N1 and H9N2 avian flu viruses were treated with hypericin at 3.72 mg/ml for 30 minutes, hypericin killed 100% of the viruses. When these viruses were treated with hypericin at 0.744 mg/ml for 10 minutes, hypericin killed over 99.99% of the viruses.

Laiwang Zhang, President and Chairman of Sunwin International Neutraceuticals, Inc., stated, "The approval could pave the way for Hypericin as a commercial application for the treatment of livestock populations in China. If approved, the demand for Hypericin should increase substantially worldwide. Furthermore, the new application can lead to successful development of the new medicine will not only help prevent the epidemic on birds and control the spread in those places which have reported outbreaks, but also can give some idea and experience to the development of new drug for human."

Mr. Zhang concluded, "We expect the demand for hypericin is tremendous for months to come upon the approval, as the Chinese government has announced it would spend $1 billion in the fight against bird flu virus. Currently, the company is producing several tons every year and is able to produce approximately 100 to 150 tons per year. The company is able to add the production up to 300 tons production capability per year within months if the market demand increases. The market price of hypericin is approximately $50,000 per ton."

About Sunwin International Neutraceuticals, Inc.

Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN) is engaged in the areas of essential traditional Chinese medicine, 100% organic herbal medicine, neutraceutical products, low-calorie natural sweetener (Stevia), and veterinary medicines and feeds prepared from 100% organic herbal ingredients. As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumer to provide a quality and a hybrid mix of agricultural products and services that meet growing demand. In 2002, Sunwin was recognized as one of the first 2,000 state-level companies that China authorized as the most important innovative high-tech pioneer businesses by the Chinese central government. In 2002, Sunwin was awarded as one of 2002 state-level biological product manufacturers in China. In 2003, Sunwin ranked as one of the top 50 companies of China Animal Related Health Care Product Pharmaceutical Industry. In 2003, Sunwin received award of Shandong Top-Ten Innovative, High-Tech Businesses by the Province Government of Shandong. For more info about Sunwin, please visit

Safe Harbor Statement

Certain of the statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact Information